Hematologic Changes in Patients with Graves’ disease in Gorgan During 2014-2015

Maryam Zahedi, Farzam Mirkamali, Sharabeh Hezarkhani, Armineh Motiee, Arash Rezaei Shahmirzadi, Mohammad Hadi Molseghi, Reza Alipoor

Abstract

Background: The most common cause of hyperthyroidism in areas without iodine deficiency is Graves’ disease. There are reports of some hematological alterations in hyperthyroidism. This study was designed to measure the hematologic profile in the patients with Graves’ disease before and after the treatment.

Methods: In this cross-sectional study, 100 patients were selected with convenience sampling that diagnosed as autoimmune Graves’ disease in our academic endocrinology clinic during 2014-2015. Inclusion criteria included autoimmune hyperthyroidism in patients who were referred to this center during the study period. Patients who refused to take part in the research, had recent infections disease, malignancies, surgical procedures, severe trauma, received immunosuppressive drugs or corticosteroids, high erythrocyte sedimentation rate (ESR) values during the last six months, and not responded to treatment with methimazole were excluded from the study. The simple sampling technique was used to select the patients.   A complete blood count (CBC) was taken before and after treatment. The P-value less than 0.05 was considered as the statistical significance level. All data were analyzed using the Statistical Package for the Social Sciences 16.0 (SPSS Inc., Chicago, IL, USA) software.

Results: One hundred patients with a mean age of 38 ± 9.8 years were included. There were no significant changes in the white blood cells (WBC) count, red blood cells (RBC) count, and platelets. Mild anemia (Hb=12.16±1.23) present before treating the hyperthyroidism that was significantly improved after treatment (P= 0.000). 

Conclusions: Our results showed that the only significant hematologic change in patients with Graves’ disease was mild anemia that improves after treating the underlying thyroid disorder. 

Keywords

Hyperthroidism, anemia, treatment, Graves’ disease

Full Text:

PDF

References

Gianoukakis AG, Leigh MJ, Richards P, Christenson PD, Hakimian A, Fu P, et al. Characterization of the anaemia associated with Graves’ disease. Clin Endocrinol 2009;70(5):781-7.

Fumarola A, Di Fiore A, Dainelli M, Grani G, Calvanese A. Medical treatment of hyperthyroidism: state of the art. Exp Clin Endocrinol Diabetes. 2010;118(10):678-84.

Dasgupta S, Savage M. Evaluation of management of Graves' disease in district general hospital: achievement of consensus guidelines. Int J Clin Pract. 2005;59(9):1097-100.

Zahediasl S, Habibi G, Ghasemi A, Rad SP, Shiva N. Hematological parameters and osmotic fragility of red blood cells in experimentally induced hyperthyroidism in rats. Int J Endocrinol Metab. 2010;8(2):74-8.

Refaat B. Prevalence and characteristics of anemia associated with thyroid disorders in non-pregnant Saudi women during the childbearing age: a cross-sectional study. Biomed J. 2015;38(4):307.

Iddah M, Macharia B, Ng’wena A, Keter A, Ofulla A. Thryroid hormones and hematological indices levels in thyroid disorders patients at Moi teaching and referral hospital, Western Kenya. ISRN endocrinol. 2013;2013.

Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, Rezayati M. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med. 2010;33(5):271-9.

Lima CS, Wittmann DEZ, Castro V, Tambascia MA, Lorand-Metze I, Saad ST, et al. Pancytopenia in untreated patients with Graves' disease. Thyroid. 2006;16(4):403-9.

Klein JR. Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid. Autoimmunity. 2003;36(6-7):417-21.

Bağriaçik EÜ, Klein JR. The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RBhigh lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol. 2000;164(12):6158-65.

Aminorroaya A, Janghorbani M, Amini M, Hovsepian S, Tabatabaei A, Fallah Z. The prevalence of thyroid dysfunction in an iodine-sufficient area in Iran. Arch Iran Med. 2009;12(3):262-70.

Dorgalaleh A, Mahmoodi M, Varmaghani B. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Ped Hematol Oncol. 2013;3(2):73.

Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, Rezayati M. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med. 2010;33(5):271-9.

Refbacks

  • There are currently no refbacks.